MINNEAPOLIS / Sep 06, 2023 / Business Wire / DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders, today announced that Rick Pauls, its President and CEO will be participating at Lake Street Capital Market’s 7th Annual Best Ideas Growth (BIG7) Conference in New York, on September 14, 2023. Management will conduct one-on-one meetings with investors during the conference.
To receive additional information or to schedule a one-on-one meeting, please contact your Lake Street Capital Markets representative.
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. DiaMedica’s lead candidate DM199 is the first pharmaceutically active and clinically studied recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke and other vascular diseases. For more information visit our website at www.diamedica.com.
| Last Trade: | US$5.26 |
| Daily Change: | -0.20 -3.66 |
| Daily Volume: | 48,996 |
| Market Cap: | US$224.920M |
November 13, 2024 November 13, 2024 October 09, 2024 August 07, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
